Humacyte, Inc. SEC filings HUMA
Humacyte, Inc. has 504 filings in SEC EDGAR's recent list, going back to Aug 4, 2020. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 28, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Other events
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 9, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Listing notice
|
May 8, 2026 | May 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 24, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 19, 2026 | Mar 19, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Mar 19, 2026 | Mar 19, 2026 |
| 8-K |
Current report
Material agreement
|
Dec 16, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Dec 15, 2025 | Dec 15, 2025 |
| 8-K |
Current report
Agreement ended
|
Dec 15, 2025 | Dec 15, 2025 |
| 8-K |
Current report
Agreement ended
|
Nov 26, 2025 | Nov 21, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 7, 2025 | Oct 6, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 18, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 11, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 18, 2025 | Apr 17, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2025 | Mar 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 26, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Other events
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 20, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 14, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2024 | Nov 8, 2024 |
| 8-K |
Current report
Other events
|
Oct 28, 2024 | Oct 28, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 7, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 25, 2024 | Sep 24, 2024 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 13, 2024 | Aug 9, 2024 |
| 8-K |
Current report
Other events
|
Jul 31, 2024 | Jul 31, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 13, 2024 | Jun 11, 2024 |
| 8-K |
Current report
Results of operations
|
May 10, 2024 | May 10, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 22, 2024 | Mar 22, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 4, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Other events
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Other events
|
Feb 9, 2024 | Feb 9, 2024 |
| 8-K |
Current report
Other events
|
Dec 12, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Other events
|
Sep 12, 2023 | Sep 12, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 8-K |
Current report
Other events
|
Jul 26, 2023 | Jul 26, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Results of operations
|
May 12, 2023 | May 12, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2023 | Mar 24, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 12, 2022 | Dec 8, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 20, 2022 | Sep 15, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2022 | Aug 12, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2022 | Jun 9, 2022 |
| 8-K |
Current report
Results of operations
|
May 13, 2022 | May 13, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K/A |
Amended current report
Officer or director change
|
Dec 28, 2021 | Dec 20, 2021 |
| 8-K |
Current report
Officer or director change
|
Dec 27, 2021 | Dec 20, 2021 |
| 8-K |
Current report
Other events
|
Nov 15, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2021 | Aug 27, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Officer or director change, Bylaw or fiscal year change
|
Aug 30, 2021 | Aug 26, 2021 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 25, 2021 | Aug 24, 2021 |
| 8-K |
Current report
Other events
|
Aug 17, 2021 | Aug 17, 2021 |
| 8-K |
Current report
Other events
|
Aug 4, 2021 | Aug 4, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 7, 2021 | Jun 4, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 26, 2021 | May 22, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2021 | May 21, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 20, 2021 | May 19, 2021 |
| 8-K |
Current report
Restatement, Other events
|
May 13, 2021 | May 7, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 6, 2021 | May 6, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 21, 2021 | Apr 21, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 14, 2021 | Mar 5, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 5, 2021 | Mar 5, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 17, 2021 | Feb 17, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Feb 17, 2021 | Feb 17, 2021 |
| 8-K |
Current report
Other events
|
Nov 6, 2020 | Nov 6, 2020 |
| 8-K |
Current report
Other events
|
Sep 28, 2020 | Sep 22, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Sep 22, 2020 | Sep 17, 2020 |
Showing 80 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- HUMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1818382
- Former names
- Alpha Healthcare Acquisition Corp. (until Aug 26, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.